Gupta Pratibha D, Tilekar Kalpana N, Upadhyay Neha M, C S Ramaa
Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, CBD Belapur, Navi Mumbai - 400614, India.
Infect Disord Drug Targets. 2022;22(8):19-29. doi: 10.2174/1871526522666220420092618.
It is a formidable challenge to treat tuberculosis as there are increasing cases of multidrugresistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) cases. Moreover, the emergence of totally drug-resistant tuberculosis (TDR-TB) makes it vital and imperative to develop a new generation of anti-tubercular drugs to have control over resistance. The nitrogencontaining heterocyclic class of compounds is being studied extensively to ascertain their anti-TB potentials. Nitrogen-containing compounds have a broad range of targets; wherein, InhA is the most important one. Hence, the primary focus of this review is to summarize the recent developments in the discovery of nitrogen-containing heterocyclic compounds as InhA inhibitors to combat tuberculosis.
治疗结核病是一项艰巨的挑战，因为耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）的病例不断增加。此外，全耐药结核病（TDR-TB）的出现使得开发新一代抗结核药物以控制耐药性变得至关重要且刻不容缓。含氮杂环类化合物正在被广泛研究，以确定它们的抗结核潜力。含氮化合物有广泛的靶点；其中，InhA是最重要的一个。因此，本综述的主要重点是总结作为InhA抑制剂用于对抗结核病的含氮杂环化合物发现方面的最新进展。
